Short description: Secondary malig neo bone. ICD-9-CM 198.5 is a billable medical code that can be used to indicate a diagnosis on a reimbursement claim, however, 198.5 should only be used for claims with a date of service on or before September 30, 2015.
2015 ICD-9-CM Diagnosis Code 199.1. Other malignant neoplasm without specification of site. ICD-9-CM 199.1 is a billable medical code that can be used to indicate a diagnosis on a reimbursement claim, however, 199.1 should only be used for claims with a date of service on or before September 30, 2015.
There are often multiple ICD-10 codes for a given ICD-9 code, so use caution! Contents. 1 Oncology, solid tumor cancer diagnoses. 1.1 Metastases to locations; ... 198.5 Metastasis to bone and/or marrow 198.3 Metastasis to brain and/or spinal cord 197.7 Metastasis to liver 197.0 Metastasis to lung 196.9 Metastasis to lymph nodes NOS
Nov 11, 2015 · We calculated sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) of bone metastases ICD-9 code 198.5. The technology-enabled abstraction displays portions of the chart to clinically trained abstractors for targeted review, thereby maximizing efficiency.
195.2 Abdominal cavity#N#173.5 Abdominal wall (skin)#N#154.3 Anus (anal)#N#156.9 Biliary tract (cholangiocarcinoma), unspecified site#N#188.9 Bladder, unspecified site#N#233.7 Bladder, in situ#N#191.9 Brain, unspecified site#N#174.9 Breast, female, unspecified site#N#233.0 Breast, in situ (DCIS)#N#175.9 Breast, male, unspecified site#N#162.9 Bronchus, unspecified site#N#180.9 Cervix (cervival), unspecified site#N#233.1 Cervix uteri, in situ#N#170.9 Chondrosarcoma#N#153.9 Colon (colorectal), unspecified site#N#182.0 Endometrium (endometrial)#N#150.9 Esophagus (esophageal), unspecified site#N#170.9 Ewing's sarcoma#N#159.9 Gastrointestinal tract, unspecified site#N#184.9 Genital, female, unspecified site#N#187.9 Genital, male, unspecified site#N#153.9 Intestine (bowel), large, unspecified site#N#152.9 Intestine (bowel), small, unspecified site#N#176.9 Kaposi's Sarcoma, unspecified site#N#189.0 Kidney (renal)#N#155.0 Liver (hepatocellular), primary#N#155.2 Liver, not specified as primary or secondary#N#162.9 Lung (adenocarcinoma/squamous cell carcinoma), unspecified site#N#209.36 Merkel cell carcinoma#N#145.9 Mouth, unspecified site#N#147.9 Nasopharynx, unspecified site#N#170.9 Osteosarcoma#N#183.0 Ovary (ovarian)#N#157.9 Pancreas (pancreatic), unspecified part#N#163.8 Pleura/contiguous sites#N#185 Prostate#N#233.4 Prostate, in situ#N#154.1 Rectum#N#158.0 Retroperitoneum#N#171.9 Rhabdosarcoma#N#142.9 Salivary gland, unspecified site#N#171.9 Sarcoma, connective or soft tissue#N#172.9 Skin, melanoma, unspecified site#N#173.9 Skin, unspecified malignancy, unspecified site#N#151.9 Stomach, unspecified site#N#186.9 Testis (testicular), unspecified site#N#195.1 Thorax#N#193 Thyroid#N#141.9 Tongue, unspecified site#N#199.1 Unknown primary#N#179 Uterus (uterine), unspecified site.
207.00 Acute erythremia & erythroleukemia#N#207.00 Acute lymphoid leukemia (ALL)#N#206.00 Acute monocytic leukemia#N#205.00 Acyte myeloid leukemia (AML)#N#208.00 Acute leukemia, unspecified#N#277.30 E85.9 Amyloidosis#N#208.10 Chronic leukemia, unspecified#N#204.10 Chronic lymphoid leukemia (CLL)#N#206.10 Chronic monocytic leukemia#N#205.10 Chronic myeloid leukemia (CML)#N#202.40 Hairy cell leukemia#N#207.20 Megakaryocytic leukemia#N#273.1 D47.2 Monoclonal gammopathy of undetermined significance (MGUS)#N#203.00 C90.0 [0-2] Multiple myeloma (MM)#N#203.10 C90.1 [0-2] Plasma cell leukemia.
284.11 Antineoplastic chemotherapy induced pancytopenia#N#285.3 Antineoplastic chemotherapy induced anemia#N#995.29 Complication of chemotherapy#N#999.81 Extravasation of vesicant chemotherapy#N#V07.39 Need for other prophylactic chemotherapy#N#V58.11 Encounter for antineoplastic chemotherapy#N#V66.2 Convalescence following chemotherapy#N#V67.2 Follow-up examination following chemotherapy#N#V87.41 Personal history of antineoplastic chemotherapy.
Types of primary osteoporosis include the following: • Postmenopausal osteoporosis (ICD-9-CM code 733.01) is caused by a lack of estrogen and affects women aged 51 to 75. • Senile osteoporosis (733.01) results from age-related calcium deficiency and occurs in people older than 70; it’s twice as common in women as in men.
A bone disease is considered any condition that affects the skeletal system and can range from very serious, requiring prompt treatment, to chronic conditions that may cause limited range of motion, deformity, or pain. Some of the more common bone diseases are discussed here. Osteoporosis. Osteoporosis, the most common bone disease, is an abnormal ...
Osteoporosis has no symptoms until a fracture occurs. If the fracture is determined to be due to osteoporosis, it is considered a pathological fracture, which is a break of a diseased or weakened bone without any identifiable trauma or following a minor injury that would not ordinarily break a healthy bone.
If the fracture is determined to be due to osteoporosis, it is considered a pathological fracture, which is a break of a diseased or weakened bone without any identifiable trauma or following a minor injury that would not ordinarily break a healthy bone.
Other underlying causes of pathological fractures include metastatic tumor of the bone, osteomyelitis, Paget’s disease, disuse atrophy, hyperparathyroidism, and nutritional or congenital disorders.
• Drug-induced osteoporosis (733.09) can be caused by corticosteroids, heparin, barbiturates, and anticonvulsants.
A primary malignant neoplasm that overlaps two or more contiguous (next to each other) sites should be classified to the subcategory/code .8 ('overlapping lesion'), unless the combination is specifically indexed elsewhere.
Thyroid cancer metastatic to bone. Clinical Information. Cancer that has spread from the original (primary) tumor to the bone. The spread of a malignant neoplasm from a primary site to the skeletal system. The majority of metastatic neoplasms to the bone are carcinomas.
All neoplasms are classified in this chapter, whether they are functionally active or not. An additional code from Chapter 4 may be used, to identify functional activity associated with any neoplasm. Morphology [Histology] Chapter 2 classifies neoplasms primarily by site (topography), with broad groupings for behavior, malignant, in situ, benign, ...